Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
Фаза 3
Идёт, набор закрыт
NCT03395197
| Заболевание | mCRPC |
|---|
| Фаза | Фаза 3 |
|---|
| Спонсор | Pfizer |
|---|
| Статус | Идёт, набор закрыт |
|---|
| Участники | 1,054 участн. |
|---|
| Вмешательство | Talazoparib with enzalutamide, Placebo with enzalutamide |
|---|
| Дата начала | 18.12.2017 |
|---|
| Дата завершения | 3.10.2022 |
|---|
| Публикация результатов | 17.01.2024 |
|---|
Кратко
This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide.
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Occuring Within the First 66 Days of Dosing - Part 1
Post dose on Day 1 up to Day 66 in Part 1 · Participants
| Part 1: Talazoparib 1 mg QD+Enzalutamide | 13 Participants |
|---|
| Part 1: Talazoparib 0.5 mg QD+Enzalutamide | 6 Participants |
|---|
| Part 1: Talazoparib 1 mg QD+Enzalutamide | 0 Participants |
|---|
| Part 1: Talazoparib 0.5 mg QD+Enzalutamide | 0 Participants |
|---|
| Part 1: Talazoparib 1 mg QD+Enzalutamide | 1 Participants |
|---|
| Part 1: Talazoparib 0.5 mg QD+Enzalutamide | 0 Participants |
|---|
Number of Participants With All-Causality Clustered Treatment-Emergent Cytopenias by Preferred Term (PT) and Max CTCAE Grade Occuring Within the First 66 Days of Dosing - Part 1
Post dose on Day 1 up to Day 66 in Part 1 · Participants
| Part 1: Talazoparib 1 mg QD+Enzalutamide | 2 Participants |
|---|
| Part 1: Talazoparib 0.5 mg QD+Enzalutamide | 0 Participants |
|---|
| Part 1: Talazoparib 1 mg QD+Enzalutamide | 6 Participants |
|---|
| Part 1: Talazoparib 0.5 mg QD+Enzalutamide | 1 Participants |
|---|
| Part 1: Talazoparib 1 mg QD+Enzalutamide | 1 Participants |
|---|
| Part 1: Talazoparib 0.5 mg QD+Enzalutamide | 0 Participants |
|---|
Number of Participants With All-Causality TEAEs During the Overall Period of Part 1
Post dose on Day 1 up to 28 days after the last dose of study intervention, or before new systemic antineoplastic therapy, whichever occurred first (maximum of 235.14 weeks) · Participants
| Part 1: Talazoparib 1 mg QD+Enzalutamide | 13 Participants |
|---|
| Part 1: Talazoparib 0.5 mg QD+Enzalutamide | 6 Participants |
|---|
| Part 1: Talazoparib 1 mg QD+Enzalutamide | 0 Participants |
|---|
| Part 1: Talazoparib 0.5 mg QD+Enzalutamide | 0 Participants |
|---|
| Part 1: Talazoparib 1 mg QD+Enzalutamide | 6 Participants |
|---|
| Part 1: Talazoparib 0.5 mg QD+Enzalutamide | 3 Participants |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.